On May 2, 2022 XNK Therapeutics AB ("XNK") reported that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association (EHA) (Free EHA Whitepaper)’s hybrid conference EHA (Free EHA Whitepaper)2022, which is held in Vienna, Austria, on June 9th-12th (Press release, XNK Therapeutics, MAY 2, 2022, View Source [SID1234613341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up, will be presented by the first author Johan Lund at a poster session on Friday, June 10, 16:30 – 17:45 CEST. The other authors include Hareth Nahi, Stephan Meinke, Per-Henrik Holmqvist, Hans-Gustaf Ljunggren, Johan Aschan and Evren Alici.

"We are very happy to be able to present this clinical long-term follow-up at this prestigious conference. It further strengthens our belief in this exciting clinical program, which also includes an ongoing clinical Phase II combination study with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab)", said XNK’s CMO Johan Aschan.

On May 2, 2022 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, reported it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets (Press release, Novavax, MAY 2, 2022, https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-and-operational-highlights-on-may-9-2022-301537188.html [SID1234613340]). Details of the event and replay are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast

On May 2, 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows (Press release, Regeneron, MAY 2, 2022, View Source [SID1234613339]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities Healthcare Conference at 1:20 p.m. PT (4:20 p.m. ET) on Tuesday, May 10, 2022
Goldman Sachs 43rd Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, June 14, 2022
The sessions may be accessed from the "Investors & Media" page of Regeneron’s website at View Source Replays of the webcasts will be archived on the Company’s website for at least 30 days.

On May 2, 2022 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1st, at the New York Hilton Midtown in New York (Press release, Johnson & Johnson, MAY 2, 2022, View Source;johnson-to-participate-in-the-bernstein-38th-annual-strategic-decisions-conference-301537487.html [SID1234613338]). Joaquin Duato, Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48-hrs after the live webcast.

On May 2, 2022 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will present new preclinical data on PH-894 for use in adoptive cell therapy (ACT) at the American Society for Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 25th Annual Meeting, which is being held May 16-19, 2022 in-person in Washington, D.C. and virtually (Press release, Phio Pharmaceuticals, MAY 2, 2022, View Source [SID1234613337]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Logo – View Source

Poster Details are as follows:

Title:

Self-Delivering RNAi Targeting BRD4 (PH-894) Improves the
Phenotype of HER2-CAR-T Cells During Expansion

Author:

Benjamin Cuiffo, et al.

Abstract Number:

222

Session:

Oligonucleotide Therapeutics I

Session Date and Time:

Monday, May 16, 2022 5:30 PM – 6:30 PM EDT

Location:

Walter E. Washington Convention Center, Hall D